Data from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer

• DOI: 10.1158/1078-0432.c.7447762.v1
• Publication Date: 2024-09-13T08:25:55Z
• Authors: Logan D. Stone; Benjamin B. Kasten; Shilpa Rao; Manuel. L. Gonzalez; Todd M. Stevens; Diana Lin; William Carroll; Benjamin Greene; Lindsay S. Moore; Andrew Fuson; Sherin James; Yolanda E. Hartman; Susan McCammon; Bharat Panuganti; Lisle M. Nabell; Yufeng Li; Mei Li; Luke Bailey; Eben L. Rosenthal; Harishanker Jeyar...; Carissa M. Thomas; Jason M. Warram
• Keywords: Interim; Transoral robotic surgery; Panitumumab

<div>AbstractPurpose:<p>The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has continually increased during the past several decades. Using transoral robotic surgery (TORS) significantly improves functional outcomes relative to open for OPSCC. However, TORS limits tactile feedback, which is often most important element cancer surgery. Fluorescence-guided (FGS) strategies aid surgeon assessment malignancy resection are in various phases clinical research but exhibit greatest potential impact improving patient care when receives limited such as TORS. Here, we assessed feasibility intraoperative fluorescence imaging using panitumumab-IRDye800CW (PAN800) patients with OPSCC.</p>Patients and Methods:<p>Twelve consecutive OPSCC were enrolled part a nonrandomized, prospective, phase II FGS trial PAN800. was performed an integrated robot camera fluorescence. Intraoperative <i>ex vivo</i> signals tumors normal tissue quantified correlated histopathology.</p>Results:<p>Intraoperative views delineated from throughout procedure (10.7 mean tumor-to-background ratio), including low expression molecular target. Tumor-specific consistent surgeon-defined tumor borders requiring resection. revealed fragment initially overlooked based on brightfield views, further substantiating benefit this approach.</p>Conclusions:<p>The results cohort support solid tumors.</p></div>